INTERVENTION 1:	Intervention	0
Cycle 0: HSP-130 3mg	Intervention	1
Participants who had not received background chemotherapy treatment in the study were administered a single dose of 3 mg of HSP-130 SC at Day 1 of Cycle 0. Participants were followed approximately 30 days after last dose of study treatment.	Intervention	2
day	UO:0000033	138-141
day	UO:0000033	200-203
INTERVENTION 2:	Intervention	3
Cycles 0: HSP-130 6mg	Intervention	4
Participants who had not received background chemotherapy treatment in the study were administered a single dose of 6 mg of HSP-130 SC at Day 1 of Cycle 0. Participants were followed approximately 30 days after last dose of study treatment.	Intervention	5
day	UO:0000033	138-141
day	UO:0000033	200-203
Inclusion Criteria:	Eligibility	0
A subject will be eligible for study participation if all of the following criteria are met at Screening:	Eligibility	1
Is informed, has been given ample time and opportunity to read about participation in the study and has signed and dated the written informed consent form approved by an Independent Ethics committee (IEC) prior to any study related activities	Eligibility	2
time	PATO:0000165	34-38
Females  18 years	Eligibility	3
Histologically confirmed and documented invasive breast cancer	Eligibility	4
breast cancer	DOID:1612	49-62
Breast cancer without evidence of distant metastases (Stage 4) based on staging work-up	Eligibility	5
breast cancer	DOID:1612	0-13
Chemotherapy naive, who have not received chemotherapy in the neoadjuvant setting and who are candidates for chemotherapy in the adjuvant setting of taxane/cyclophosphamide-based regimen, e.g., TAC, as background chemotherapy	Eligibility	6
adjuvant	CHEBI:60809	65-73
adjuvant	CHEBI:60809	129-137
Zubrod/WHO/ECOG performance status  2	Eligibility	7
Adequate bone marrow, hepatic, and renal function reserve as evidenced by:	Eligibility	8
bone marrow	UBERON:0002371	9-20
function	BAO:0003117,BFO:0000034	41-49
Hemoglobin  10 mg/dl	Eligibility	9
hemoglobin	CHEBI:35143	0-10
ANC  1.5 x 10^9/L	Eligibility	10
x	LABO:0000148	9-10
Platelet count of  100 x 10^9/L	Eligibility	11
platelet count	CMO:0000029	0-14
x	LABO:0000148	23-24
Total bilirubin  2 mg/dl	Eligibility	12
Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)  3 x the upper limit of normal (ULN) of the reference lab	Eligibility	13
aspartate	CHEBI:29995	0-9
alanine	CHEBI:16449	37-44
x	LABO:0000148	71-72
Serum creatinine of  1.5 x ULN for reference lab or estimated glomerular filtration rate (eGFR) of  60 mg/min	Eligibility	14
creatinine	CHEBI:16737	6-16
x	LABO:0000148	25-26
glomerular filtration	GO:0003094	62-83
rate	BAO:0080019	84-88
Body mass index (BMI) of 19 to 40 kg/m^2 , inclusive	Eligibility	15
Subjects of childbearing potential, and their partners, agree to pregnancy prevention throughout the duration of the study (through the Follow-up Visit). Specific type of pregnancy prevention should be discussed with, and acceptable to, the treating oncologist in the context of the tumoral hormone receptor status. Subjects and their partners must agree to use of an effective method of contraception, to avoid impregnation of females throughout the course of the study	Eligibility	16
duration	PATO:0001309	101-109
hormone	CHEBI:24621	291-298
receptor	BAO:0000281	299-307
Medically acceptable forms of birth control can include, with approval of the treating physician:	Eligibility	17
Barrier methods (condom or diaphragm with spermicide)	Eligibility	18
diaphragm	UBERON:0001103	27-36
Intrauterine device (IUD)	Eligibility	19
Hormone contraceptives (such as oral [pill], injection, skin patch, implant, cervical ring)	Eligibility	20
hormone	CHEBI:24621	0-7
Subjects using oral contraceptives must be on a stable regimen for at least 3 months prior to Screening. Sexually active subjects must use contraception while on HSP-130 from admission to the final Follow-up Visit	Eligibility	21
stable	HP:0031915	48-54
active	PATO:0002354	114-120
Able to understand verbal or written instructions and comply with all study requirements, to communicate effectively with study personnel and is available for the planned duration of the study	Eligibility	22
duration	PATO:0001309	171-179
Exclusion Criteria:	Eligibility	23
A subject will NOT be eligible for study participation if any of the following criteria are met at Screening:	Eligibility	24
Previous G-CSF exposure, including filgrastim, lenograstim, pegfilgrastim, lipegfilgrastim, granulocyte/macrophage colony stimulating growth factor (GM-CSF), or any other branded or biosimilar G-CSF	Eligibility	25
growth factor	BAO:0002024	134-147
Prior autologous stem cell harvest of any type	Eligibility	26
Drug sensitivity, allergic reaction, or known hypersensitivity or idiosyncratic reaction to E. coli - derived proteins, filgrastim, other G-CSFs, or pegylated agents	Eligibility	27
drug	CHEBI:23888	0-4
hypersensitivity	GO:0002524,DOID:1205	46-62
Known hypersensitivity to docetaxel, polysorbate 80, or doxorubicin	Eligibility	28
hypersensitivity	GO:0002524,DOID:1205	6-22
polysorbate 80	CHEBI:53426	37-51
doxorubicin	CHEBI:28748,BAO:0000639	56-67
For subjects receiving doxorubicin, no concurrent use of inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp or with trastuzumab due to increased risk of cardiac dysfunction	Eligibility	29
doxorubicin	CHEBI:28748,BAO:0000639	23-34
Chemotherapy other than that included in this study (taxane/cyclophosphamide-based regimen, e.g., TAC or TC) or neoadjuvant chemotherapy; or known immunosuppressive agents including chronic oral corticosteroid use, or radiation therapy within 4 weeks of first dose of HSP-130, prior bone marrow or stem cell transplantation, or malignancy within 5 years	Eligibility	30
chronic	HP:0011010	182-189
corticosteroid	CHEBI:50858	195-209
bone marrow	UBERON:0002371	283-294
Known HER2 + ( overexpressing breast cancer)	Eligibility	31
breast cancer	DOID:1612	30-43
Known triple negative (estrogen receptor-negative, progesterone receptor-negative and HER2-negative) breast cancer	Eligibility	32
estrogen	CHEBI:50114,BAO:0000760	23-31
progesterone	CHEBI:17026	51-63
breast cancer	DOID:1612	101-114
Grade 2 underlying neuropathy	Eligibility	33
neuropathy	DOID:870	19-29
Current diagnosis of active tuberculosis or other severe infection, such as sepsis, abscesses or opportunistic infections	Eligibility	34
active	PATO:0002354	21-27
tuberculosis	DOID:399	28-40
severe infection	HP:0032169	50-66
sepsis	HP:0100806	76-82
Treatment with systemically active antibiotics within 72 hours before chemotherapy	Eligibility	35
active	PATO:0002354	28-34
Known infection with HIV	Eligibility	36
Known sickle cell disease	Eligibility	37
disease	DOID:4,OGMS:0000031	18-25
Known severe persistent drug-induced myelosuppression	Eligibility	38
severe	HP:0012828	6-12
New York Heart Association (NYHA) class III or IV heart failure, severe uncontrolled cardiac disease (unstable angina, clinically significant ECG abnormalities) or MI within the previous 6 months before the first administration of HSP-130	Eligibility	39
heart	UBERON:0000948	9-14
heart	UBERON:0000948	50-55
severe	HP:0012828	65-71
disease	DOID:4,OGMS:0000031	93-100
Any malignancy other than breast cancer, with exception of adequately treated squamous or basal cell carcinoma of the skin or cervical carcinoma in situ, within 5 years before the first administration of the HSP-130	Eligibility	40
breast cancer	DOID:1612	26-39
basal cell carcinoma	HP:0002671,DOID:2513	90-110
carcinoma	HP:0030731,DOID:305	101-110
carcinoma	HP:0030731,DOID:305	135-144
Current or recent treatment (within 30 days before the first administration of the HSP-130) with any other investigational medicinal product	Eligibility	41
product	BAO:0003067	133-140
Pregnancy or lactation; Subjects planning to be pregnant or to breastfeed before, during, or within 12 months after administration of the HSP-130 are not permitted to enroll in the study	Eligibility	42
lactation	GO:0007595	13-22
Received a live, live-attenuated, or non-live vaccine within 4 weeks before the first administration of the HSP-130	Eligibility	43
vaccine	VO:0000001	46-53
Patient has evidence of any other coexisting disease or medical or psychological condition, metabolic dysfunction, physical examination finding or clinical lab finding giving reasonable suspicion of a disease or condition that contraindicated the use of an HSP-130, or patient is high risk for treatment complication	Eligibility	44
patient	HADO:0000008,OAE:0001817	0-7
patient	HADO:0000008,OAE:0001817	269-276
disease	DOID:4,OGMS:0000031	45-52
disease	DOID:4,OGMS:0000031	201-208
condition	PDRO:0000129	81-90
condition	PDRO:0000129	212-221
physical examination	OAE:0004232	115-135
Outcome Measurement:	Results	0
Area Under the Effect Curve for Absolute Neutrophil Count (AUECANC): Cycle 0	Results	1
area	PATO:0001323	0-4
Absolute neutrophil count (ANC) is a measure of the number of neutrophil granulocytes (also known as polymorphonuclear cells, PMN's, polys, granulocytes, segmented neutrophils or segs) present in the blood.	Results	2
present	PATO:0000467	185-192
blood	UBERON:0000178	200-205
Time frame: Cycle 0: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose	Results	3
time	PATO:0000165	0-4
hour	UO:0000032	32-36
hour	UO:0000032	69-73
Results 1:	Results	4
Arm/Group Title: Cycle 0: HSP-130 3mg	Results	5
Arm/Group Description: Participants who had not received background chemotherapy treatment in the study were administered a single dose of 3 mg of HSP-130 SC at Day 1 of Cycle 0. Participants were followed approximately 30 days after last dose of study treatment.	Results	6
day	UO:0000033	161-164
day	UO:0000033	223-226
Overall Number of Participants Analyzed: 6	Results	7
Mean (Standard Deviation)	Results	8
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: hour*10^9 Neutrophils per Liter  3900.482         (683.6870)	Results	9
hour	UO:0000032	17-21
Results 2:	Results	10
Arm/Group Title: Cycles 0: HSP-130 6mg	Results	11
Arm/Group Description: Participants who had not received background chemotherapy treatment in the study were administered a single dose of 6 mg of HSP-130 SC at Day 1 of Cycle 0. Participants were followed approximately 30 days after last dose of study treatment.	Results	12
day	UO:0000033	161-164
day	UO:0000033	223-226
Overall Number of Participants Analyzed: 6	Results	13
Mean (Standard Deviation)	Results	14
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: hour*10^9 Neutrophils per Liter  5880.985         (1287.2887)	Results	15
hour	UO:0000032	17-21
Adverse Events 1:	Adverse Events	0
Total: 0/6 (0.00%)	Adverse Events	1
Febrile Neutropenia * 0/6 (0.00%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Adverse Events 2:	Adverse Events	3
Total: 0/6 (0.00%)	Adverse Events	4
Febrile Neutropenia * 0/6 (0.00%)	Adverse Events	5
neutropenia	HP:0001875,DOID:1227	8-19
